Close
Harel Dahari

Associate Professor

Education

Affiliations

Projects

Papers

Chertow DS, Shekhtman L, Lurie Y, Davey RT, Heller T, Dahari H. (2020). Modeling Challenges of Ebola Virus-Host Dynamics during Infection and Treatment. Viruses, 12(1)

Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Cohen Eliav M, Skorochod Y, Breuer GS, Tur-Kaspa R, Weil Wiener Y, Stern A, Cotler SJ, Dahari H, Lurie Y. (2019). Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography. PloS one, 14(1)

Echevarria D, Gutfraind A, Boodram B, Layden J, Ozik J, Page K, Cotler SJ, Major M, Dahari H. (2019). Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. Vaccine, 37(19)

Lhomme S, DebRoy S, Kamar N, Abravanel F, Metsu D, Marion O, Dimeglio C, Cotler SJ, Izopet J, Dahari H. (2019). Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. Viruses, 11(7)

Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Eliav MC, Skorochod Y, Breuer GS, Tur-Kaspa R, Wiener YW, Stern A, Cotler SJ, Dahari H, Lurie Y. (2019). Correction: Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography. PloS one, 14(2)

Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ. (2019). A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral research, (163)

Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ. (2019). A Randomized, Proof-Of-Concept Clinical Trial on Repurposing Chlorcyclizine for the Treatment of Chronic Hepatitis C. Antiviral research, (163)

Tatara E, Collier NT, Ozik J, Gutfraind A, Cotler SJ, Dahari H, Major M, Boodram B. (2019). MULTI-OBJECTIVE MODEL EXPLORATION OF HEPATITIS C ELIMINATION IN AN AGENT-BASED MODEL OF PEOPLE WHO INJECT DRUGS. Proceedings of the ... Winter Simulation Conference. Winter Simulation Conference, (2019)

Reinharz V, Dahari H, Barash D. (2018). Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics. Mathematical biosciences, (300)

Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, Dahari H. (2018). Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users. Science translational medicine, 10(449)

Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, Forns X, Dahari H. (2019). Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. Liver international : official journal of the International Association for the Study of the Liver, 39(5)

Dahari H, Boodram B. (2018). How to eliminate HCV in people who inject drugs in the USA. The Lancet. Infectious diseases, 18(2)

Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H. (2018). High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members. Journal of urban health : bulletin of the New York Academy of Medicine, 95(1)

Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H, Chayama K. (2017). HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients. PloS one, 12(12)

Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H. (2017). Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral research, (144)

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H. (2017). Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatology communications, 1(4)

Reinharz V, Churkin A, Dahari H, Barash D. (2017). A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics. Frontiers in applied mathematics and statistics, (3)

Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P. (2016). HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. Journal of hepatology, 64(6)

Dahari H, Cotler SJ, Feld JJ. (2016). Cure prevents more than transmission of hepatitis C virus. Hepatology (Baltimore, Md.), 64(3)

Dahari H, Halfon P, Cotler SJ. (2016). Resurrection of response-guided therapy for sofosbuvir combination therapies. Journal of hepatology, 65(3)

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, Dahari H. (2015). Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago. PLoS One, 10(8)

Graw F, Martin DN, Perelson AS, Uprichard SL, Dahari H. (2015). Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach. Journal of virology, 89(13)

Dahari H, Shteingart S, Gafanovich I, Cotler SJ, D'Amato M, Pohl RT, Weiss G, Ashkenazi YJ, Tichler T, Goldin E, Lurie Y. (2015). Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver international : official journal of the International Association for the Study of the Liver, 35(2)

Dahari H, Cotler SJ. (2014). Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach. Hepatology (Baltimore, Md.), 59(6)

Canini L, DebRoy S, Mariño Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, Dahari H. (2014). Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antiviral therapy, 20(2)

Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H. (2014). Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (Baltimore, Md.), 60(6)

Guedj J, Canini L, Cotler S, Dahari H. (2015). Reply: To PMID 25098971. Hepatology (Baltimore, Md.), 61(6)

Zhang J, Lipton HL, Perelson AS, Dahari H. (2013). Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection. Journal of virology, 87(7)

Dahari H, Cotler SJ, Layden TJ, Perelson AS. (2013). Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling. Journal of hepatology, 58(4)

Dahari H, Guedj J, Perelson AS. (2011). Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved. Hepatology (Baltimore, Md.), 54(2)

Dahari H, Guedj J, Perelson AS, Layden TJ. (2011). Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. Current hepatitis reports, 10(3)

Dahari H, Affonso de Araujo ES, Haagmans BL, Layden TJ, Cotler SJ, Barone AA, Neumann AU. (2010). Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. Journal of hepatology, 53(3)

Dahari H, Feinstone SM, Major ME. (2010). Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology, 139(3)

Dahari H, Cotler SJ, Layden TJ, Perelson AS. (2009). Hepatitis B virus clearance rate estimates. Hepatology (Baltimore, Md.), 49(5)

Burg D, Rong L, Neumann AU, Dahari H. (2009). Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection. Journal of theoretical biology, 259(4)

Dahari H, Sainz B Jr., Perelson AS, Uprichard SL. (2009). Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. Journal of virology, 83(13)

Dahari H, Layden-Almer JE, Kallwitz E, Ribeiro RM, Cotler SJ, Layden TJ, Perelson AS. (2009). A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology, 136(4)

Dahari H, Shudo E, Cotler SJ, Layden TJ, Perelson AS. (2009). Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antiviral therapy, 14(3)

Dahari H, Shudo E, Ribeiro RM, Perelson AS. (2009). Mathematical modeling of HCV infection and treatment. Methods in molecular biology (Clifton, N.J.), (510)

Dahari H, Shudo E, Ribeiro RM, Perelson AS. (2009). Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology (Baltimore, Md.), 49(1)

Dahari H, Layden-Almer JE, Perelson AS, Layden TJ. (2008). Hepatitis C Viral Kinetics in Special Populations. Current hepatitis reports, 7(3)

Dahari H, Ribeiro RM, Perelson AS. (2007). Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology (Baltimore, Md.), 46(1)

Dahari H, Lo A, Ribeiro RM, Perelson AS. (2007). Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. Journal of theoretical biology, 247(2)

Dahari H, Perelson AS. (2007). Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology (Baltimore, Md.), 46(6)

Dahari H, Perelson AS. (2007). Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss. World journal of gastroenterology, 13(21)

Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, Perelson AS, Talal AH. (2007). Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. Journal of hepatology, 47(1)

Dahari H, Ribeiro RM, Rice CM, Perelson AS. (2007). Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. Journal of virology, 81(2)

Dahari H, Forns X, Neumann AU, Perelson AS. (2006). The extrahepatic contribution to HCV plasma viremia. Journal of hepatology, 45(4)

Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU. (2005). Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. Journal of hepatology, 42(4)

Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, Feinstone SM, Neumann AU. (2005). Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology, 128(4)